Genentech, Inc.

Genetech, Inc.

Tue H Nguyen

Tai Dung Nguyen

Steven J Shire

David C Cipolla

Xanthe M Lam

Michael Frank Powell

Karl Joseph Gifford

Linda R De Young

Karl Joseph Dodds Gifford

Marjorie A Mohler

Linda R DeYoung

A print head comprising two shafts disposed in opposite sides of a filament to drive the filament to a heated chamber for delivering a molten material. The shafts are actively driven, for example, by two independent motors. The two shaft configuration of the print head can improve a control of the filament movement rate, especially for soft filament materials.

3D printer systems and methods

A modular 3D printer system can include a base subsystem and multiple exchangeable components. The base subsystem can have a 3D motion module, a printhead module and a platform module. The multiple exchangeable components can include printheads having different configurations and functionalities, which can be exchangeably installed in the printhead module. The multiple exchangeable components can include platform supports having different configurations and functionalities, which can be exchangeably installed in the platform module.

Systems and methods for 3D printing with multiple exchangeable printheads

Formulations are provided comprising NGF and acetate-containing buffer from pH 5 to 6 that provide enhanced stability of NGF for use in promoting nerve cell growth, repair, survival, differentiation, maturation or function.

Stabilizing formulation for NGF

A pharmaceutical composition is provided wherein human relaxin is formulated at an acidic pH of about 4 to less than about 7. The composition, useful for effecting parturition and inhibiting premature delivery, includes a buffer capable of maintaining the pH of the composition within a desired range, and may also include an agent to make the composition isotonic, and a stabilizing agent, if necessary. A specific example is human relaxin formulated in a citrate buffer, pH about 5.0, in the presence of sodium chloride, at an ionic strength of about 0.15 .mu..

Human relaxin formulation

A method and pharmaceutical composition for the prevention of fibrin deposition or adhesion formation by topical application of a composition to a site of potential fibrin deposition or adhesion formation comprising a sparingly soluble enzyme that is continuously released at that site for a period of time of from about three days to two weeks which may include an inert adherence enhancing vehicle.

Growing community of inventors

San Mateo, CA, United States of America

Tue H Nguyen